Topics of Discussion:
- Biomarker Testing in 2016
- Liquid Biopsies: Emerging Role: NGS, RT PCR, DNA, RNA, CTC’s and more
- Targeted Therapies: EGFR
- Targeted Therapies: ALK
- Non-Driver Adenocarcinoma
- Panel Case Discussion 1: Adenocarcinoma
- Checkpoint Inhibitors
- Monoclonal Antibodies Targeting Angiogenesis and EGFR
- Other New Therapies and Combinations (RET, BRAF, CMET, NTRK, etc)
- Panel Case Discussion 2: Squamous Cell Carcinoma
